Brainstorm Cell Therapeutics (NASDAQ:BCLI) Coverage Initiated at StockNews.com

Equities researchers at StockNews.com initiated coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a report issued on Sunday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Performance

NASDAQ:BCLI opened at $1.56 on Friday. The company has a market capitalization of $8.90 million, a PE ratio of -0.33 and a beta of 0.26. The company has a 50 day simple moving average of $1.97 and a two-hundred day simple moving average of $2.42. Brainstorm Cell Therapeutics has a fifty-two week low of $1.05 and a fifty-two week high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.